MX2013002718A - Composiciones de anticuerpo anti-vegfr-3. - Google Patents

Composiciones de anticuerpo anti-vegfr-3.

Info

Publication number
MX2013002718A
MX2013002718A MX2013002718A MX2013002718A MX2013002718A MX 2013002718 A MX2013002718 A MX 2013002718A MX 2013002718 A MX2013002718 A MX 2013002718A MX 2013002718 A MX2013002718 A MX 2013002718A MX 2013002718 A MX2013002718 A MX 2013002718A
Authority
MX
Mexico
Prior art keywords
vegfr
antibody compositions
antibodies
disease
treatment
Prior art date
Application number
MX2013002718A
Other languages
English (en)
Inventor
Bronislaw Pytowski
Krishnadatt Persaud
Nathalie Zayek
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013002718(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of MX2013002718A publication Critical patent/MX2013002718A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a anticuerpos monoclonales anti-VEGFR-3, composiciones farmacéuticas que contienen los anticuerpos y usos de los anticuerpos en el tratamiento de enfermedades.
MX2013002718A 2010-09-07 2011-09-01 Composiciones de anticuerpo anti-vegfr-3. MX2013002718A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07
PCT/US2011/050131 WO2012033696A1 (en) 2010-09-07 2011-09-01 Anti-vegfr-3 antibody compositions

Publications (1)

Publication Number Publication Date
MX2013002718A true MX2013002718A (es) 2013-05-01

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002718A MX2013002718A (es) 2010-09-07 2011-09-01 Composiciones de anticuerpo anti-vegfr-3.

Country Status (25)

Country Link
US (2) US8481034B2 (es)
EP (1) EP2614081B1 (es)
JP (1) JP2013538813A (es)
KR (1) KR20130042601A (es)
CN (1) CN103080133A (es)
AR (1) AR082641A1 (es)
AU (1) AU2011299443B2 (es)
BR (1) BR112013005423A2 (es)
CA (1) CA2809375C (es)
CL (1) CL2013000607A1 (es)
CO (1) CO6690754A2 (es)
CR (1) CR20130065A (es)
DO (1) DOP2013000039A (es)
EA (1) EA023331B1 (es)
EC (1) ECSP13012481A (es)
ES (1) ES2568801T3 (es)
GT (1) GT201300058A (es)
MA (1) MA34487B1 (es)
MX (1) MX2013002718A (es)
PE (1) PE20131328A1 (es)
SG (1) SG188265A1 (es)
TW (1) TWI413527B (es)
UA (1) UA109148C2 (es)
WO (1) WO2012033696A1 (es)
ZA (1) ZA201300804B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2911681A1 (en) 2012-10-26 2015-09-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물
WO2016112466A1 (en) * 2015-01-15 2016-07-21 Oncoquest Inc. Methods of increasing delivery of anti-cancer agents to targets
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219419T2 (de) * 2001-01-19 2007-08-16 Ludwig Institute For Cancer Research Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung
CA2624976A1 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies

Also Published As

Publication number Publication date
CL2013000607A1 (es) 2014-04-11
CA2809375A1 (en) 2012-03-15
AU2011299443A1 (en) 2013-02-14
SG188265A1 (en) 2013-04-30
AU2011299443B2 (en) 2014-06-05
GT201300058A (es) 2014-07-16
CA2809375C (en) 2016-02-09
US20130280278A1 (en) 2013-10-24
EA201390117A1 (ru) 2013-06-28
KR20130042601A (ko) 2013-04-26
US8481034B2 (en) 2013-07-09
US8784818B2 (en) 2014-07-22
BR112013005423A2 (pt) 2016-06-07
UA109148C2 (uk) 2015-07-27
CR20130065A (es) 2013-03-21
CO6690754A2 (es) 2013-06-17
MA34487B1 (fr) 2013-08-01
EA023331B1 (ru) 2016-05-31
WO2012033696A1 (en) 2012-03-15
JP2013538813A (ja) 2013-10-17
AR082641A1 (es) 2012-12-19
TWI413527B (zh) 2013-11-01
PE20131328A1 (es) 2013-11-18
ECSP13012481A (es) 2015-03-31
EP2614081A1 (en) 2013-07-17
TW201223543A (en) 2012-06-16
ZA201300804B (en) 2014-07-30
US20120058126A1 (en) 2012-03-08
DOP2013000039A (es) 2013-04-15
EP2614081B1 (en) 2016-03-16
ES2568801T3 (es) 2016-05-04
CN103080133A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
TN2015000396A1 (en) Antibody drug conjugates
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
NZ707086A (en) Anti-cd40 antibodies and methods of use
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
PH12017500864A1 (en) Anti-notch1 antibodies
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MY163521A (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
MA34091B1 (fr) Anticorps anti-cd40
MX347020B (es) Anticuerpo contra el csf-1r.
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MX2013009151A (es) Inmunoterapia mejorada.
WO2014163714A3 (en) Antibody drug conjugates
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
TN2015000277A1 (en) Bmp-6 antibodies
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions